LIVER: Edited by Don C. RockeyDirect-acting antiviral treatment for patients with hepatocellular carcinomaKushner, Tatyana; Dieterich, Douglas; Saberi, BehnamAuthor Information Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA Correspondence to Behnam Saberi, MD, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Room 11-70, Box 1123, New York, NY 10029, USA. Tel: +212 659 9219; fax: +212 849 2574; e-mail: [email protected] Current Opinion in Gastroenterology: May 2018 - Volume 34 - Issue 3 - p 132-139 doi: 10.1097/MOG.0000000000000431 Buy Metrics Abstract Purpose of Review Hepatocellular carcinoma (HCC) affects a significant portion of patients with hepatitis C. The use of direct-acting antiviral (DAA) agents has transformed the disease outcomes in this patient group. Recent Findings Hepatitis C virus (HCV) response to DAAs can be affected by the presence of HCC, whereas DAA therapy may affect the risk of HCC recurrence in patients with a history of HCC. Summary Emerging data are demonstrating lower sustained virologic response (SVR) rates in patients with HCC compared with patients without HCC. Conflicting studies have also suggested that rates of HCC recurrence in patients with a history of HCC can potentially be increased or decreased on DAA therapy. This review will provide a brief overview of these data and inform practitioners on important considerations to make when prescribing DAA therapy for patients with HCV and HCC. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.